Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | -100.0% |
| 2020 | 1 Million USD | -2.15% |
| 2019 | 1.02 Million USD | -62.93% |
| 2018 | 2.75 Million USD | 220.58% |
| 2017 | 860 Thousand USD | 151.46% |
| 2016 | 342 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q3 | 417 Thousand USD | -97.88% |
| 2023 Q2 | 19.64 Million USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 Q1 | - USD | -100.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q3 | - USD | -100.0% |
| 2022 Q2 | 292 Thousand USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2021 FY | - USD | -100.0% |
| 2021 Q2 | 33 Thousand USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q4 | 570 Thousand USD | 481.63% |
| 2021 Q3 | 98 Thousand USD | 196.97% |
| 2020 Q1 | - USD | 100.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | -100.0% |
| 2020 FY | 1 Million USD | -2.15% |
| 2020 Q2 | 1 Million USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q1 | 1.02 Million USD | -26.53% |
| 2019 FY | 1.02 Million USD | -62.93% |
| 2019 Q4 | -1.02 Million USD | 0.0% |
| 2019 Q2 | - USD | -100.0% |
| 2018 Q2 | 22 Thousand USD | -93.17% |
| 2018 FY | 2.75 Million USD | 220.58% |
| 2018 Q4 | 1.39 Million USD | 36.11% |
| 2018 Q3 | 1.02 Million USD | 4545.45% |
| 2018 Q1 | 322 Thousand USD | -62.56% |
| 2017 Q1 | 22 Thousand USD | 0.0% |
| 2017 Q2 | 22 Thousand USD | 0.0% |
| 2017 Q3 | 22 Thousand USD | 0.0% |
| 2017 Q4 | 860 Thousand USD | 3809.09% |
| 2017 FY | 860 Thousand USD | 151.46% |
| 2016 FY | 342 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 100.0% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 100.0% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 100.0% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 100.0% |
| Better Therapeutics, Inc. | -2.72 Million USD | 100.0% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 100.0% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 100.0% |
| Gene Biotherapeutics, Inc. | - USD | NaN% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 100.0% |
| Eloxx Pharmaceuticals, Inc. | - USD | NaN% |
| Evelo Biosciences, Inc. | - USD | NaN% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 100.0% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 100.0% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 100.0% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | 100.0% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 100.0% |
| Molecular Templates, Inc. | 50.39 Million USD | 100.0% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 100.0% |
| NexImmune, Inc. | -1.02 Million USD | 100.0% |
| Orgenesis Inc. | -5.72 Million USD | 100.0% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 100.0% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | 100.0% |
| PaxMedica, Inc. Common Stock | - USD | NaN% |
| Scopus BioPharma Inc. | - USD | NaN% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 100.0% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 100.0% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 100.0% |
| Trevena, Inc. | 1.45 Million USD | 100.0% |
| Vaxxinity, Inc. | -2.23 Million USD | 100.0% |
| Vaccinex, Inc. | -16 Million USD | 100.0% |
| Vicapsys Life Sciences, Inc. | - USD | NaN% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 100.0% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 100.0% |